Mumbai: Pharma major Lupin Limited (Lupin) announced today the successful completion of an inspection carried out by the U.S. FDA at its Aurangabad, India facility. The inspection was carried out between February 10, 2020 and February 14, 2020.
The inspection concluded without any observation.
Commenting on the outcome of the inspection, Nilesh Gupta, Managing Director, Lupin said, “We are encouraged with the successful inspection at our Aurangabad facility. We continue to enhance our standards of quality and compliance across our manufacturing operations and remain committed to uphold the highest quality standards across all our sites”.
About Lupin Limited
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.
The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women’s health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions and in India by global revenues. The Company invests 9.6 % of its revenues on research and development.
Lupin has 15 manufacturing sites, seven research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.
Please visit www.lupin.com for more information.
Follow us on
For further information or queries please contact –
Head – Investor Relations and Corporate Communications
Tel: +91-22 6640 8237
General Manager – Corporate Communications
Tel: +91-22-6640 2532